entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 22:07:46 - browse：5419

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Cord blood banking comes at a high cost to babies

Wikipedia

focus

WSS

Let's speed up science by embracing open access publishing

ASCO: AstraZeneca says CAR

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Wegovy leads to weight loss. Can it treat depression, too?

focus

entertainment

knowledge

Guidelines to prevent youth baseball injuries need more muscle

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FTC sues over Novant Health acquisition of two N.C. hospitals

Medical records are filled with copy

See how much Covid

At least 13 dead in Texas as scorching temps continue

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

focus

How to increase colonoscopy rates? Looks like an AI can help

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

HIV drugs protect against transmission, even in unprotected sex

With trial win, GSK could get blood cancer drug back on market

At ASCO, AstraZeneca reports strong data for breast cancer drug

The Pandemic Treaty must support building strong health systems

Wikipedia

explore

focus

entertainment